Targeted Radionuclide Therapy of Human Tumors

International Journal of Molecular Sciences

Sergey V. Gudkov²  Natalya Yu. Shilyagina²  Vladimir A. Vodeneev²  Andrei V. Zvyagin²  William Chi-shing Cho¹ 

[1] Laboratory of Optical Theranostics, Lobachevsky Nizhny Novgorod State University, Gagarin Ave. 23, Nizhny Novgorod 603950, RussiaLaboratory of Optical Theranostics, Lobachevsky Nizhny Novgorod State University, Gagarin Ave. 23, Nizhny Novgorod 603950, Russia;

关键词: radio-immunotherapy;    radionuclide;    targeted therapy;    α-emitter;    β-emitter;    Auger electron;    antibody;    peptide;   

DOI  :  10.3390/ijms17010033

来源: mdpi

【 摘 要 】

Targeted radionuclide therapy is one of the most intensively developing directions of nuclear medicine. Unlike conventional external beam therapy, the targeted radionuclide therapy causes less collateral damage to normal tissues and allows targeted drug delivery to a clinically diagnosed neoplastic malformations, as well as metastasized cells and cellular clusters, thus providing systemic therapy of cancer. The methods of targeted radionuclide therapy are based on the use of molecular carriers of radionuclides with high affinity to antigens on the surface of tumor cells. The potential of targeted radionuclide therapy has markedly grown nowadays due to the expanded knowledge base in cancer biology, bioengineering, and radiochemistry. In this review, progress in the radionuclide therapy of hematological malignancies and approaches for treatment of solid tumors is addressed.

【 授权许可】

CC BY   
© 2015 by the authors; licensee MDPI, Basel, Switzerland.